Wegovy Click Dosage Chart: Reading the Schedule Correctly

What the licensed dose schedule actually says

The Wegovy escalation ladder was established through the STEP clinical trial programme, whose largest study (STEP 1, published in the New England Journal of Medicine) followed 1,961 adults over 68 weeks and recorded an average body-weight reduction of around 15% at the 2.4 mg maintenance dose alongside lifestyle support. The pace of escalation in that trial, mirroring the licensed schedule, was not arbitrary: it was designed specifically to let the body adapt and reduce the likelihood of gastrointestinal side effects.

The schedule the MHRA licences runs as follows. Treatment opens at 0.25 mg once weekly for four weeks. That starting strength is a tolerability measure, its job is to settle your system, not to produce significant weight loss. After four weeks the dose steps to 0.5 mg for four weeks, then to 1.0 mg, then to 1.7 mg, reaching the 2.4 mg maintenance level around week 17. At each rung the prescriber can pause the increase if side effects are not settling, so the actual timing in practice may extend beyond the minimum. The NHS medicines page for semaglutide sets out this schedule for patients clearly.

In 2026, the MHRA approved a higher 7.2 mg dose, first as three 2.4 mg pens per week, then via a dedicated single-dose pen confirmed on 14 April 2026. That level is for adults with a BMI of 30 or above, and the titration to reach it follows the same staged principle. Whether it is appropriate for a given patient is a clinical decision, not one a dosage chart can resolve. For further detail on the full range of Wegovy strengths available in the UK, the Wegovy doses guide covers each level in context.

How the click mechanism works on each pen

The phrase "click dosage" reflects how the Wegovy pen delivers its dose: one press of the injection button releases the full pre-set amount. There is no dial to turn, no number to set. Each pen strength comes pre-filled with a single fixed dose, a 0.25 mg pen delivers 0.25 mg at that one click, a 2.4 mg pen delivers 2.4 mg. You cannot split a pen across two injections or adjust the volume.

This design removes a common source of error. A patient moving from 1.7 mg to 2.4 mg does not adjust anything, they simply start using the next pen in the sequence, as their prescriber directs. The pen locks after use and should be disposed of in a sharps container. The needle should be changed with every injection. Injection sites rotate between the abdomen, thigh and upper arm to minimise local reactions.

Storage matters too: Wegovy pens are refrigerated at 2–8 °C. The manufacturer's Patient Information Leaflet gives the exact window for keeping a pen at room temperature before use, always defer to that document rather than a secondary source, because the window has specific conditions attached. A practical habit many patients find helpful: keep the current pen on the fridge shelf where it is visible, and check the injection day against a phone reminder rather than relying on memory.

If you are looking at how a specific dose's click chart translates to your injection day, the Wegovy clicks dosage chart maps each pen strength to the corresponding injection schedule, while the Wegovy click dosage page and the Wegovy dosage chart provide dose-level reference in more detail.

What a click chart cannot tell you, and who can

A dosage chart is a reference tool. It shows the prescribed sequence; it does not tell you what to do if you inject late, if you feel unwell after a dose increase, or if your prescriber decides to hold you at a lower level for longer. Those decisions depend on clinical context that no chart captures.

The NICE appraisal of semaglutide for weight management (NICE TA875) notes that treatment should be reconsidered if a patient has not achieved at least 5% weight loss after six months at the maintenance dose. That threshold is assessed by a clinician, not derived from the click count on a pen. Similarly, questions about missed doses, travel storage, interactions with other medicines, and what happens if you need surgery all sit with your prescriber, the Patient Information Leaflet is the primary reference for day-to-day use.

If you are considering whether Wegovy is the right treatment, or you are looking to transfer from another provider, understanding the dose schedule is a useful start. For a broader picture of how semaglutide compares with other licensed options and what treatment through a regulated pharmacy looks like, the Wegovy overview covers the full clinical context. The Wegovy price guide addresses what private treatment costs as a starting point for that conversation. And if you have general questions about how the clinical process works at nume (sorry, at a GPhC-registered pharmacy) the FAQs are a practical next stop.

When you are ready to discuss suitability with a prescriber rather than a chart, check your eligibility through a free consultation, a named clinician, not a form-processing system, reads your responses the same day.